Lenalidomide

Approved Uses

Lenalidomide is primarily used to treat the following conditions:

• Multiple Myeloma: It is used in combination with dexamethasone to treat patients with multiple myeloma. It is also used alone as a maintenance therapy for patients who have received an autologous hematopoietic stem cell transplant.
• Myelodysplastic Syndromes (MDS): It is used to treat patients with anemia who require blood transfusions due to low-to-intermediate-1 risk MDS associated with a specific genetic change called a deletion 5q cytogenetic abnormality.
• Mantle Cell Lymphoma (MCL): It is used for patients with MCL whose disease has come back or progressed after at least two prior treatments, including the drug bortezomib.
• Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL): It is used in combination with a rituximab product to treat patients who have previously received treatment for these types of lymphoma.

Mechanism of Action

Lenalidomide belongs to a class of drugs known as immunomodulatory agents. It works through several different pathways to treat cancers of the blood and bone marrow:

• Boosting the immune system: It enhances the activity of specific immune cells, such as T cells and natural killer cells, which are responsible for identifying and destroying abnormal or cancerous cells.
• Starving tumors: It has anti-angiogenic properties, meaning it prevents the development of new blood vessels. Since tumors require a blood supply to grow and spread, blocking these vessels helps limit tumor expansion.
• Directly stopping cell growth: The medication can interfere with the growth signals inside certain cancer cells, leading to their death or preventing them from multiplying.
• Regulating chemical messengers: It affects the production of cytokines, which are chemicals in the body that control inflammation and the environment in which cancer cells thrive.

Common Side Effects

Many people taking lenalidomide experience mild to moderate side effects. These may include:

• Diarrhea, constipation, or stomach pain
• Nausea and vomiting
• Loss of appetite and weight loss
• Feeling very tired or weak
• Dizziness or headache
• Muscle cramps, joint pain, or back pain
• Dry skin, itching, or a mild rash
• Swelling of the hands, feet, or lower legs
• Cough, sore throat, or shortness of breath
• Difficulty falling asleep or staying asleep
• Fever

Serious Side Effects

Lenalidomide can cause serious health problems that require immediate medical attention. Contact a doctor right away if you experience:

• Low blood cell counts: Signs include fever, chills, sore throat, unusual bruising, or bleeding.
• Blood clots: Symptoms may include chest pain, sudden shortness of breath, or pain and swelling in the arms or legs.
• Severe skin reactions: A red or purple rash that spreads and causes blistering or peeling, which may be accompanied by a fever.
• Liver problems: Yellowing of the eyes or skin (jaundice), dark urine, or pain in the upper right stomach area.
• Tumor lysis syndrome: Signs include fast or irregular heartbeat, decreased urination, or confusion.
• Allergic reactions: Hives, swelling of the face or throat, or difficulty breathing.
• Heart attack or stroke: Symptoms include chest pressure, numbness on one side of the body, or slurred speech.

This medication may also increase the risk of developing other types of cancer, such as certain types of leukemia or skin cancer, during or after treatment.

Boxed Warnings

Lenalidomide has several boxed warnings due to the risk of serious side effects:

• Embryo-Fetal Toxicity: This medication can cause severe, life-threatening birth defects or death to an unborn baby. It must not be used during pregnancy. Both men and women must follow strict pregnancy prevention measures.
• Hematologic Toxicity: It can cause a significant decrease in white blood cells (neutropenia) and platelets (thrombocytopenia), which increases the risk of infection and bleeding.
• Venous and Arterial Thromboembolism: There is an increased risk of blood clots in the veins, such as deep vein thrombosis, and arteries, such as heart attack or stroke.

Restricted Distribution (REMS)

Because of the risk of fetal exposure, lenalidomide is only available through a restricted program. Patients, prescribers, and pharmacies must be registered and meet specific requirements to use or dispense this medication.

Severe Allergic and Skin Reactions

Serious skin reactions, including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported. These conditions can be fatal. Treatment should be stopped immediately if a severe rash or allergic reaction occurs.

Liver Injury

Liver failure and other forms of liver injury have occurred in patients taking lenalidomide. Monitoring of liver function is typically required during treatment.

Second Primary Malignancies

Patients treated with lenalidomide may have a higher risk of developing new types of cancer, such as acute myelogenous leukemia (AML) or certain skin cancers.

Tumor Flare Reaction

In some conditions, such as chronic lymphocytic leukemia (CLL) or lymphoma, the drug may cause a tumor flare, where the cancer symptoms temporarily worsen. This may involve tender lymph nodes, low-grade fever, or skin rash.

Pregnancy Risks

Lenalidomide is structurally similar to thalidomide, a drug known to cause severe birth defects. Taking even a single dose of lenalidomide during pregnancy can cause life-threatening birth defects or the death of an unborn baby. Because of these risks, the medication is only available through a restricted distribution program called REMS.

For individuals who can become pregnant, the following requirements typically apply:

• Negative pregnancy tests are required before starting treatment, at regular intervals during treatment, and after finishing the medication.
• Two forms of effective birth control must be used simultaneously, or the individual must commit to total abstinence from heterosexual intercourse, for at least 4 weeks before starting, during treatment, during dose interruptions, and for at least 4 weeks after stopping the drug.

For males taking lenalidomide:

• The drug is present in semen. A latex or synthetic condom must be used during any sexual contact with a person who can become pregnant, even if the male has had a successful vasectomy. This requirement applies during treatment and for 4 weeks after the last dose.
• Sperm donation is prohibited while taking this medication and for 4 weeks after stopping.

Breastfeeding

It is not known whether lenalidomide passes into human breast milk. Due to the potential for serious side effects in a nursing child, healthcare providers typically advise against breastfeeding while using this medication. Patients should discuss the risks and benefits of treatment with their healthcare team if they are nursing or planning to nurse.

Available Forms

Lenalidomide is available as a capsule to be taken by mouth. It is designed for oral use and should be swallowed whole according to a healthcare provider's instructions.

Administration Considerations

• The capsules should not be opened, crushed, or chewed.
• If a capsule is broken or leaking, avoid contact with the powder inside.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved lenalidomide for the treatment of several types of cancer. Its primary indications include:

• Multiple Myeloma: It is used in combination with dexamethasone for patients with multiple myeloma. It is also approved as a maintenance treatment following autologous hematopoietic stem cell transplantation.
• Myelodysplastic Syndromes (MDS): It is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality.
• Mantle Cell Lymphoma: It is used for patients whose disease has returned or progressed after two prior therapies.
• Follicular and Marginal Zone Lymphoma: It is approved for use in combination with rituximab for patients previously treated for these conditions.

Boxed Warnings and Safety Regulations

Lenalidomide carries serious safety warnings mandated by the FDA:

• Embryo-Fetal Toxicity: Due to its similarity to thalidomide, lenalidomide can cause severe birth defects or fetal death. It is strictly contraindicated in pregnant women.
• Blood Toxicities: The medication can cause severe neutropenia (low white blood cells) and thrombocytopenia (low platelets).
• Blood Clots: There is an increased risk of deep vein thrombosis, pulmonary embolism, heart attack, and stroke.

Restricted Distribution (REMS)

To manage the risk of fetal exposure, lenalidomide is only available through a restricted distribution program. All prescribers, pharmacies, and patients must be enrolled in this program and follow strict requirements regarding pregnancy testing and the use of contraception.

Factors Influencing Price

The price of lenalidomide depends on several variables, including the pharmacy used and the specific treatment plan. Because it is a specialized medication, it is often more expensive than common prescriptions.

• Generic vs. Brand Name: Generic lenalidomide is available and is generally more affordable than the brand-name version, Revlimid.
• Insurance and Medicare: Most prescription drug plans cover lenalidomide, but patients may still face significant out-of-pocket costs depending on their plan's deductible and copayment tiers.
• Specialty Pharmacy: This medication is distributed through a restricted program (REMS) and must be obtained through certified specialty pharmacies, which may have different pricing structures than local retail pharmacies.

Financial Support Options

Many patients utilize assistance programs to help manage the cost of lenalidomide. Options may include manufacturer patient assistance programs, copay assistance for those with private insurance, and grants from independent charitable foundations.